Back to search
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Relapsed/Refractory Multiple Myeloma (RRMM)
Clinicaltrials.gov:
Other:
#64007957MMY4004
Interested in this trial?
Email or download this trial
Trials at a glance
Status
Enrolling
Condition
Relapsed/Refractory Multiple Myeloma (RRMM)
Trial type
Observational
Trial phase
N/A
Investigational
product
product
Talquetamab
Teclistamab
Age
18+ years old
Biological sex
All
Placebo?
No
Trial start date
December 18, 2023
Trial end date
October 23, 2026
CT.gov ID
#NCT06285318
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Denmark,
- France,
- Germany,
- Greece,
- Ireland,
- Israel,
- Italy,
- Norway,
- Spain,
- Sweden,
- United Kingdom
Loading...
Enrolling
Aalborg 2624886, Denmark, 9100
Enrolling
Aarhus N 11746890, Denmark, 8200
Enrolling
Thessaloniki 734077, Greece, 54636
Enrolling
Oslo 3143244, Norway, 1478
Enrolling
Athens 264371, Greece, 115 28
Enrolling
Thessaloniki 734077, Greece, 546 39
Enrolling
Napoli 9031661, Italy, 80131
Enrolling
Trieste 3165185, Italy, 34128
Enrolling
Bolzano 3181913, Italy, 39100
Enrolling
Dublin 2964574, Ireland, D18 AK68
Enrolling
Cork 2965140, Ireland, T12 DV56
Enrolling
Vandœuvre-lès-Nancy 2970797, France, 54500
Enrolling
Nantes 2990969, France, 44000
Enrolling
Thessaloniki 734077, Greece, 570 10
Enrolling
Jerusalem 281184, Israel, 9112001
Enrolling
Lille 2998324, France, 59037
Enrolling
Vigo 3105976, Spain, 36213
Enrolling
Valencia 2509954, Spain, 46010
Enrolling
Ávila 3129136, Spain, 05071
Enrolling
Granada 2517117, Spain, 18014
Enrolling
Madrid 3117735, Spain, 28046
Enrolling
Madrid 3117735, Spain, 28006
Enrolling
Milan 6951411, Italy, 20252
Enrolling
Toulouse 2972315, France, 31100
Enrolling
Ioannina 261779, Greece, 45500
Enrolling
Stockholms, Sweden, 12559
Enrolling
Chemnitz 2940132, Germany, 09116
Enrolling
Hanover 2910831, Germany, 30459
Enrolling
Athens 264371, Greece, 115 27
Enrolling
Odense 2615876, Denmark, 5000
Enrolling
Brindisi 3181528, Italy, 72100
Enrolling
Salerno 3168673, Italy, 84098
Enrolling
Treviso 3165201, Italy, 31100
Enrolling
Verbania 6457398, Italy, 28922
Enrolling
Vicenza 3164419, Italy, 36100
Enrolling
Lecce 3174953, Italy, 73100
Enrolling
Gothenburg 2711537, Sweden, 413 45
Enrolling
Ramat Gan 293788, Israel, 52621
Enrolling
Tel Aviv 293397, Israel, 6423906
Enrolling
Wolverhampton 2633691, United Kingdom, WV10 0QP
Enrolling
Uddevalla 2666670, Sweden, 451 98
Enrolling
Heidelberg 2907911, Germany, 69120
Enrolling
Roma 8957247, Italy, 00168
Enrolling
Galway 2964180, Ireland, H91 YR71
Enrolling
Hamburg 2911298, Germany, 20246
Enrolling
Larissa 258576, Greece, 413 34
Enrolling
Alexandroupoli 736928, Greece, 68100
Enrolling
Heraklion 261745, Greece, 715 00
Enrolling
Tønsberg 3134331, Norway, 3103
Completed
Florence 3176959, Italy, 50141
Completed
Palermo 2523920, Italy, 90146
Completed
Cork 2965140, Ireland, 00000
Completed
London 2643743, United Kingdom, SE1 9RT
Completed
Paris 2988507, France, 75475
Completed
Málaga 2514256, Spain, 29603
Completed
Marseille 2995469, France, 13009
Completed
Nuremberg 2861650, Germany, 90419
Completed
Jönköping 2702979, Sweden, 551 85
Completed
Bologna 3181928, Italy, 40138
Completed
Milan 6951411, Italy, 20121
Completed
Roma 8957247, Italy, 65124
Completed
Birmingham 2655603, United Kingdom, B15 2GW
Completed
Copenhagen 2618425, Denmark, 2100
Completed
Dublin 2964574, Ireland, D08 NHY1
Completed
Vejle 2610613, Denmark, 7100
Completed
Dresden 2935022, Germany, 01307
Completed
London 2643743, United Kingdom, NW1 2PG
Completed
Würzburg 2805615, Germany, 97080
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2025
